Lower-grade gliomas surgery guided by GRPR-targeting PET/NIR dual-modality image probe: a prospective and single-arm clinical trial

作者：Liangpeng Chen, Jingjing Zhang, Chongwei Chi, Wenqiang Che, Gehong Dong, Junmei Wang, Yanru Du, Rongxi Wang, Zhaohui Zhu, Jie Tian, Nan Ji, Xiaoyuan Chen, Deling Li · 发表于：Theranostics · 年份：2024 · DOI：10.7150/thno.91554 · 被引用次数：26 · 研究领域：Glioma Diagnosis and Treatment、Nanoplatforms for cancer theranostics、Cancer Research and Treatments

Purpose: Lower-grade gliomas (LGGs) are a group of infiltrative growing glial brain tumors characterized by intricate intratumoral heterogeneity and subtle visual appearance differences from non-tumor tissue, which can lead to errors in pathologic tissue sampling.Although 5-ALA fluorescence has been an essential method for visualizing gliomas during surgery, its effectiveness is limited in the case of LGGs due to low sensitivity.Therefore, we developed a novel PET/NIR dual-modality image probe targeting gastrin-releasing peptide receptor (GRPR) in glioma cells to enhance tumor visualization and improve the accuracy of sampling.Methods: A prospective, non-randomized, single-center feasibility clinical trial (NCT 03407781) was conducted in the referral center from October 21, 2016, to August 17, 2018.Consecutive enrollment included patients suspected of having LGGs and considered suitable candidates for surgical removal.Group 1 comprised ten patients who underwent preoperative 68 Ga-IRDye800CW-BBN PET/MRI assessment followed by intraoperative fluorescence-guided surgery.Group 2 included 42 patients who underwent IRDye800CW-BBN fluorescence-guided surgery.The primary endpoints were the predictive value of preoperative PET imaging for intraoperative fluorescence and the sensitivity and specificity of fluorescence-guided sampling.Results: Thirty-nine patients were included in the in-depth analysis of endpoints, with 25 (64.1%)exhibiting visible fluorescence, while 14 (35.9%) did n...